Letrozol Stada (Letrozole)

Letrozol Stada is an aromatase inhibitor indicated for conditions driven by estrogen production.

• Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen synthesis to inhibit tumor growth.
• Adjuvant therapy for early‑stage breast cancer: helps prevent disease recurrence after surgery.
• Metastatic breast cancer: provides disease control when used with other systemic agents.

• Letrozole reversibly binds to the aromatase enzyme, blocking the conversion of androgens to estrogens in peripheral tissues. By lowering circulating estrogen levels, it deprives estrogen‑dependent tumor cells of a growth stimulus, thereby slowing or halting disease progression in hormone‑sensitive breast cancer.

Letrozol Stada may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects

• Hot flashes: sudden feeling of warmth, often with sweating.
• Joint and muscle pain: arthralgia or myalgia.
• Fatigue: persistent tiredness.
• Nausea: mild to moderate upset stomach.
• Headache: pressure or throbbing pain.
• Dizziness: light‑headed sensation.

Serious or Rare Side Effects

• Severe liver injury: jaundice, elevated enzymes.
• Bone fracture: increased risk due to lowered estrogen.
• Pulmonary embolism: sudden shortness of breath, chest pain.
• Allergic reaction (anaphylaxis): hives, swelling, airway compromise.
• QT interval prolongation: cardiac rhythm disturbance.

Before initiating Letrozol Stada, clinicians should consider several safety measures.

• Assess bone health: monitor for osteoporosis and consider calcium/vitamin D supplementation.
• Monitor liver function: check transaminases periodically.
• Evaluate cardiovascular risk: watch for signs of thromboembolic events.
• Avoid use in premenopausal women: drug is ineffective without postmenopausal estrogen levels.
• Pregnancy warning: contraindicated in pregnancy; effective contraception required.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Letrozol Stada can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Concurrent tamoxifen: antagonistic effect on estrogen blockade.
• Strong CYP2C19 inhibitors (e.g., fluconazole): may raise letrozole plasma levels.
• Hormone replacement therapy: diminishes letrozole’s therapeutic effect.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of anticoagulant effect; monitor INR.
• CYP3A4 inducers (e.g., rifampin): may lower letrozole concentrations.
• Selective serotonin reuptake inhibitors: monitor for additive central nervous system effects.